E-MAIL: [email protected]
How can we prove that irradiated COP vials have a low adsorption rate for protein drugs?
062025.11
FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs
FDA-Approved Biosimilar Products,the approval of biosimilar products can improve access to care for patients by increasing t...
FDA Approves Expanded Use of Vonvendi for von Willebrand Disease, Including for Certain Uses for Children
Copyright © Shijiazhuang Xinfuda Medical Packaging Co., Ltd. All Rights
Reserved Powered by
MAKE AN ENQUIRY
